AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Karyopharm Therapeutics Inc. Director's Dealing 2025

Oct 16, 2025

34529_dirs_2025-10-16_cd6fe015-356f-40ba-b514-e7b20f17f2e9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Karyopharm Therapeutics Inc. (KPTI)
CIK: 0001503802
Period of Report: 2025-10-15

Reporting Person: Paulson Richard A. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-15	Common Stock	A	114285	—	Acquired	198331	Direct

Footnotes

F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026.